Nuvectis Pharma, Inc. (NVCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$24.49+0.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NVCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -32.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NVCT — earnings miss
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…
Why it matters: New clinical data may improve NXP200's appeal to investors.
Supportive ifGood clinical data will be shared at the ESMO conference in October 2026.
Worry ifThe clinical data shown does not prove strong efficacy or safety.
Why it matters: The IND submission is key for ciprocopan's path to U.S. marketing approval. This could open up a significant market for Nuvectis.
Supportive ifThe IND submission occurs as planned in 4Q2026.
Worry ifThe IND submission is delayed beyond 4Q2026.
Why it matters: Watching cash burn is key to understanding financial health and staying in business.
Worry ifCash burn goes down a lot from Q2 2026 levels.
Less concerning ifCash burn remains high or increases despite the new funding.
Why it matters: Data from this study will show how well NXP900 works, impacting future funding and development.
Supportive ifData will be shared as planned in summer 2026.
Worry ifNo data will be shared. There are also no major delays.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$315 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $554 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,680 loss on $10,000 · 36.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Funding is crucial for Nuvectis to continue its operations and development. Clear plans can reassure investors.
Supportive ifA new announcement talks about funding or partnerships. This will help operations until 2H 2027.
Worry ifNo news or bad updates about funding plans for operations into 2H 2027.
Why it matters: These updates will show if Nuvectis can expand its pipeline and market presence. Positive news can enhance growth prospects.
Supportive ifA press release detailing positive progress in the development of NXP100 and NXP200.
Worry ifA press release showed delays or problems in developing these compounds.